Pneumoconiosis Market Research Report – Forecast till 2027

Pneumoconiosis Market Research Report, By Type (Asbestosis, Berylliosis, Byssinosis, Coal Workers Pneumoconiosis, Silicosis), Cause (Organic Dusts, Non-Organic Substances), Therapy (Diagnosis, Treatment), End User (Hospital) - Forecast till 2027

ID: MRFR/Pharma/3218-HCR | February 2021 | Region: Global | 90 pages

Pneumoconiosis Market Scenario:


Pneumoconiosis is a restrictive and occupational lung disease caused by inhalation of dust. There are a number of different agents that, when inhaled, can potentially cause pneumoconiosis. Organic and inorganic agents are responsible for causing this diseases. According to the Centers for Disease Control and Prevention, in 2013, 260,000 deaths occurred due to pneumoconiosis. Increasing prevalence of pneumoconiosis, increasing smoking population, and rising air pollution have driven the growth of the market. Approximately 75% of non-asbestos pneumoconiosis cases recorded under the IIDB scheme in 2009 were from individuals that are over 65 years. According to the Centers for Disease Control and Prevention, cigarette smoking is the leading cause of death in the United States, accounting for over 480,000 deaths every year. Moreover, increasing geriatric population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, smoking increases the possibility of pneumoconiosis; more than 60% of the global population smokes, this has increased the risk of pneumoconiosis and contributed in the growth of the market. However, side effects associated with the treatment and lack of long term treatment may lead to hinder the growth of the market.


The pneumoconiosis market is expected to grow at a CAGR of 6.8% during forecast period. 


Intended Audience



  • Biotechnological institutes

  • Pharmaceutical companies

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories


Figure 1:- Global Pneumoconiosis market share, by causes Pneumoconiosis Market

Sources: WHO, annual reports, press release, white paper, and company presentation 


Segmentation


The pneumoconiosis market is segmented on the basis of types, causes, therapy, and end users.


On the basis of types, the pneumoconiosis market is segmented into asbestosis, berylliosis, byssinosis, coal workers pneumoconiosis, silicosis, and others.


On the basis of causes, the pneumoconiosis market is categorised into organic dusts, non-organic substances, and others. Organic substances are further segmented into hay, malt, mushrooms, and others. Non organic substances are further segmented into sulphur dioxide, ammonia, nitrogen dioxide, and others.


On the basis of therapy, the pneumoconiosis market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest X-ray, CT scan, and others. Treatment is further classified into mucolytic agent, antibiotic, and others.


On the basis of end users, the pneumoconiosis market is segmented into hospital, clinics, and others. 


Regional Analysis


America dominates the pneumoconiosis market owing to large patient population. Apart from this, increasing number of patients, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention, in 2015, about 15 in every 100 U.S. adults aged over 18 years smoked cigarettes. Which is equals around 36.5 million adults in the United States currently smoke cigarettes. Increasing smoking population increases the possibility of causing the disease. Additionally, increasing awareness among the people regarding different diagnostic procedures and well-developed technology has also contributed to the growth of the market.


Europe is the second largest pneumoconiosis market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.


Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and presence of huge opportunity in the market.


On the other hand, the Middle East & Africa has the least share in the pneumoconiosis market due to presence of poor economy especially in Africa region. Majority of the market of this region is held by Middle East due to well-developed healthcare sector and huge healthcare expenditure. 


Research Methodology
Pneumoconiosis Market-


Sources: WHO, annual reports, press release, white paper, and company presentation 


Key players for pneumoconiosis market


The key players for the pneumoconiosis market Abbott (US) Eli Lilly (U.S.), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.).


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   6.8% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Causes, Therapy, and End Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott (US) Eli Lilly (U.S.), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Novartis (Switzerland), Abbott (U.S.), AstraZeneca (U.K), Merck & Co. (U.S.), Pfizer (U.S.), Svizera Healthcare (India), F. Hoffman La Roche AG (Germany), and Bayer Cropscience Ltd. (U.S.)
  Key Market Opportunities

  • Increasing geriatric population
  • Increasing healthcare expenditure
  • Strong encouragement from the government
  •   Key Market Drivers

  • Increasing prevalence of pneumoconiosis
  • Increasing smoking population
  • Rising air pollution


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Pneumoconiosis market is projected to grow at a 6.8% CAGR between 2020- 2027.

    The Americas is expected to dominate the pneumoconiosis market.

    Non-organic substances, organic dusts, and others are the major causes of pneumoconiosis.

    Lack of long term treatment and certain side effects are factors that may limit the pneumoconiosis market growth.

    Leading players profiled in the pneumoconiosis market include Bayer Cropscience Ltd. (U.S.), F. Hoffman La Roche AG (Germany), Svizera Healthcare (India), Pfizer (U.S.), Merck & Co. (U.S.), AstraZeneca (U.K), Abbott (U.S.), Novartis (Switzerland), Novo Nordisk (Denmark), Sanofi (France), Sunpharma (India), Sunpharma (India), and Abbott (US) Eli Lilly (U.S.).

    TABLE OF CONTENT

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Technology Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porters Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 6. Global Pneumoconiosis Market, by Type

    6.1 Introduction

    6.2 Asbestosis

    Market Estimates & Forecast, 2020 – 2027

    6.3 Berylliosis

    Market Estimates & Forecast, 2020 – 2027

    6.4 Byssinosis

    Market Estimates & Forecast, 2020 – 2027

    6.5 Coal Workers Pneumoconiosis

    Market Estimates & Forecast, 2020 – 2027

    6.6 Silicosis

    Market Estimates & Forecast, 2020 – 2027

    6.7 Others

    Market Estimates & Forecast, 2020 – 2027

    Chapter 7. Global Pneumoconiosis Market, by Causes

    7.1 Introduction

    7.2 Organic Dusts

    Market Estimates & Forecast, 2020 – 2027

    7.2.1 Hay

    7.2.2 Malt

    7.2.3 Mushrooms

    7.2.4 Others

    7.3 Non-Organic Substances

    Market Estimates & Forecast, 2020 – 2027

    7.3.1 Sulphur Dioxide

    7.3.2 Ammonia

    7.3.3 Nitrogen Dioxide

    7.3.4 Others

    7.4 Others

    Market Estimates & Forecast, 2020 – 2027

    Chapter 8. Global Pneumoconiosis Market, by Therapy

    8.1 Introduction

    8.2 Diagnosis

    Market Estimates & Forecast, 2020 – 2027

    8.2.1 X-Ray

    8.2.2 CT Scan

    8.2.3 Others

    8.3 Treatment

    Market Estimates & Forecast, 2020 – 2027

    8.3.1 Mucolytic Agent

    8.3.2 Antibiotic

    8.3.3 Others

    Chapter 9 Global Pneumoconiosis Market, by End User

    9.1 Introduction

    9.2 Hospitals

    Market Estimates & Forecast, 2020 – 2027

    9.3 Clinics

    Market Estimates & Forecast, 2020 – 2027

    9.4 Others

    Chapter 10. Global Pneumoconiosis Market, by Region

    10.1 Introduction

    10.2 America

    10.2.1 North America

    10.2.1.1 US

    10.2.1.1 Canada

    10.2.2 South America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 Republic of Korea

    10.4.6 Rest of Asia Pacific

    10.5 The Middle East & Africa

    10.5.1 United Arab Emirates

    10.5.2 Saudi Arabia

    10.5.3 Oman

    10.5.4 Kuwait

    10.5.5 Qatar

    10.5.6 Rest of the Middle East & Africa

    Chapter 11 Company Landscape

    11.1 Introduction

    11.2 Market Share Analysis

    11.3 Key Development & Strategies

    11.3.1 Key Developments

    Chapter 12 Company Profiles

    12.1 Novartis AG

    12.1.1 Company Overview

    12.1.2 Product Overview

    12.1.3 Financials

    12.1.4 SWOT Analysis

    12.2 Abbott

    12.2.1 Company Overview

    12.2.2 Product Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 Eli Lilly

    12.3.1 Company Overview

    12.3.2 Product Overview

    12.3.3 Financial Overview

    12.3.4 Key Development

    12.3.5 SWOT Analysis

    12.4 Sunpharma

    12.4.1 Company Overview

    12.4.2 Product/Business Segment Overview

    12.4.3 Financial Overview

    12.4.4 Key Development

    12.4.5 SWOT Analysis

    12.5 Sanofi

    12.5.1 Company Overview

    12.5.2 Product Overview

    12.5.3 Financial overview

    12.5.4 Key Developments

    12.6 Novo Nordisk

    12.6.1 Company Overview

    12.6.2 Product Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.7 AstraZeneca

    12.7.1 Overview

    12.7.2 Product Overview

    12.7.3 Financials

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 Others

    Chapter 13 MRFR Conclusion

    13.1 Key Findings

    13.1.1 From CEO’s View Point

    13.1.2 Unmet Needs of the Market

    13.2 Key Companies to Watch

    13.3 Prediction of Pharmaceutical industry

    Chapter 14 Appendix

    LIST OF TABLES

    Table 1 Pneumoconiosis Industry Synopsis, 2020 – 2027

    Table 2 Global Pneumoconiosis Market Estimates and Forecast, 2020 – 2027, (USD Million)

    Table 3 Global Pneumoconiosis Market by Region, 2020 – 2027, (USD Million)

    Table 4 Global Pneumoconiosis Market by Types, 2020 – 2027, (USD Million)

    Table 5 Global Pneumoconiosis Market by Causes, 2020 – 2027, (USD Million)

    Table 6 Global Pneumoconiosis Market by Therapy, 2020 – 2027, (USD Million)

    Table 7 Global Pneumoconiosis Market by End Users, 2020 – 2027, (USD Million)

    Table 8 North America Pneumoconiosis Market by Types, 2020 – 2027, (USD Million)

    Table 9 North America Pneumoconiosis Market by Causes, 2020 – 2027, (USD Million)

    Table 10 North America Pneumoconiosis Market by Therapy, 2020 – 2027, (USD Million)

    Table 11 North America Pneumoconiosis Market by End Users, 2020 – 2027, (USD Million)

    Table 12 US Market by Types, 2020 – 2027, (USD Million)

    Table 13 US Pneumoconiosis Market by Causes, 2020 – 2027, (USD Million)

    Table 14 US Pneumoconiosis Market by Therapy, 2020 – 2027, (USD Million)

    Table 15 US Pneumoconiosis Market by End Users, 2020 – 2027, (USD Million)

    Table 16 Canada Market by Types, 2020 – 2027, (USD Million)

    Table 17 Canada Pneumoconiosis Market by Causes, 2020 – 2027, (USD Million)

    Table 18 Canada Pneumoconiosis Market by Therapy, 2020 – 2027, (USD Million)

    Table 19 Canada Pneumoconiosis Market by End Users, 2020 – 2027, (USD Million)

    Table 20 South America Market by Types, 2020 – 2027, (USD Million)

    Table 21 South America Pneumoconiosis Market by Causes, 2020 – 2027, (USD Million)

    Table 22 South America Pneumoconiosis Market by Therapy, 2020 – 2027, (USD Million)

    Table 23 South America Pneumoconiosis Market by End Users, 2020 – 2027, (USD Million)

    Table 24 Europe Market by Types, 2020 – 2027, (USD Million)

    Table 25 Europe Pneumoconiosis Market by Causes, 2020 – 2027, (USD Million)

    Table 26 Europe Pneumoconiosis Market by Therapy, 2020 – 2027, (USD Million)

    Table 27 Europe Pneumoconiosis Market by End Users, 2020 – 2027, (USD Million)

    Table 28 Western Europe Market by Types, 2020 – 2027, (USD Million)

    Table 29 Western Europe Pneumoconiosis Market by Causes, 2020 – 2027, (USD Million)

    Table 30 Western Europe Pneumoconiosis Market by Therapy, 2020 – 2027, (USD Million)

    Table 31 Western Europe Pneumoconiosis Market by End Users, 2020 – 2027, (USD Million)

    Table 32 Eastern Europe Market by Types, 2020 – 2027, (USD Million)

    Table 33 Eastern Europe Pneumoconiosis Market by Causes, 2020 – 2027, (USD Million)

    Table 34 Eastern Europe Pneumoconiosis Market by Therapy, 2020 – 2027, (USD Million)

    Table 35 Eastern Europe Pneumoconiosis Market by End Users, 2020 – 2027, (USD Million)

    Table 36 Asia Pacific Market by Types, 2020 – 2027, (USD Million)

    Table 37 Asia Pacific Pneumoconiosis Market by Causes, 2020 – 2027, (USD Million)

    Table 38 Asia Pacific Pneumoconiosis Market by Therapy, 2020 – 2027, (USD Million)

    Table 39 Asia Pacific Pneumoconiosis Market by End Users, 2020 – 2027, (USD Million)

    Table 40 Middle East & Africa Market by Types, 2020 – 2027, (USD Million)

    Table 41 Middle East & Africa Pneumoconiosis Market by Causes, 2020 – 2027, (USD Million)

    Table 42 Middle East & Africa Pneumoconiosis Market by Therapy, 2020 – 2027, (USD Million)

    Table 43 Middle East & Africa Pneumoconiosis Market by End Users, 2020 – 2027, (USD Million)

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Segmentation for Global Pneumoconiosis Market

    Figure 3 Segmentation Market Dynamics for Global Pneumoconiosis Market

    Figure 4 Global Pneumoconiosis market Share, by Type 2020

    Figure 5 Global Pneumoconiosis market Share, by Causes 2020

    Figure 6 Global Pneumoconiosis market Share, by Therapy 2020

    Figure 7 Global Pneumoconiosis Market Share, by End Users, 2020

    Figure 8 Global Pneumoconiosis Market Share, by Region, 2020

    Figure 9 North America Pneumoconiosis Market Share, by Country, 2020

    Figure 10 Europe Pneumoconiosis Market Share, by Country, 2020

    Figure 11 Asia Pacific Pneumoconiosis Market Share, by Country, 2020

    Figure 12 Middle East & Africa Pneumoconiosis Market Share, by Country, 2020

    Figure 13 Global Pneumoconiosis Market: Company Share Analysis, 2020 (%)

    Figure 14 Novartis AG: Key Financials

    Figure 15 Novartis AG: Segmental Revenue

    Figure 16 Novartis AG: Geographical Revenue

    Figure 17 Abbott: Key Financials

    Figure 18 Abbott: Segmental Revenue

    Figure 19 Abbott: Geographical Revenue

    Figure 20 Eli Lilly: Key Financials

    Figure 21 Eli Lilly: Segmental Revenue

    Figure 22 Eli Lilly: Geographical Revenue

    Figure 23 Sunpharma: Key Financials

    Figure 24 Sunpharma: Segmental Revenue

    Figure 25 Sunpharma: Geographical Revenue

    Figure 26 Sanofi: Key Financials

    Figure 27 Sanofi: Segmental Revenue

    Figure 28 Sanofi: Geographical Revenue

    Figure 29 Novo Nordisk: Key Financials

    Figure 30 Novo Nordisk: Segmental Revenue

    Figure 31 Novo Nordisk: Geographical Revenue

    Figure 32 AstraZeneca: Key Financials

    Figure 33 AstraZeneca: Segmental Revenue

    Figure 34 AstraZeneca: Geographical Revenue